1. Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients
- Author
-
Ilaria Vicenti, Emanuele Montomoli, Serena Marchi, Linda Benincasa, Claudia Maria Trombetta, Emilio Bombardieri, Antonella Ruello, Maurizio Zazzi, Alessandro Manenti, and Simonetta Viviani
- Subjects
0301 basic medicine ,neutralizing activity ,COVID-19 Vaccines ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.disease_cause ,variants of concern ,Microbiology ,Antibodies ,South Africa ,03 medical and health sciences ,0302 clinical medicine ,Virology ,Chlorocebus aethiops ,Pandemic ,Animals ,Medicine ,030212 general & internal medicine ,Neutralizing antibody ,Neutralizing ,Pandemics ,Vero Cells ,Mutation ,biology ,business.industry ,SARS-CoV-2 ,Communication ,Vaccination ,Antibody titer ,COVID-19 ,Antibodies, Neutralizing ,Spike Glycoprotein ,United Kingdom ,QR1-502 ,COVID-19 Drug Treatment ,Coronavirus ,Titer ,030104 developmental biology ,Infectious Diseases ,Spike Glycoprotein, Coronavirus ,Vero cell ,biology.protein ,business ,Brazil ,Neutralizing activity ,Variants of concern - Abstract
The recent spreading of new SARS-CoV-2 variants, carrying several mutations in the spike protein, could impact immune protection elicited by natural infection or conferred by vaccination. In this study, we evaluated the neutralizing activity against the viral variants that emerged in the United Kingdom (B.1.1.7), Brazil (P.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected by SARS-CoV-2 during the first pandemic wave in Italy in 2020. Of the patients studied, 59.5% showed a decrease (≥2 fold) in neutralizing antibody titer against B.1.1.7, 83.3% against P.1, and 90.5% against B.1.351 with respect to the original strain. The reduction in antibody titers against all analyzed variants, and in particular P.1 and B.1.351, suggests that previous symptomatic infection might be not fully protective against exposure to SARS-CoV-2 variants carrying a set of relevant spike mutations.
- Published
- 2021